A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties
Preventing neuronal death is a priority for treating neurological diseases. However, therapies that inhibit pathological neuron loss could promote tumorigenesis by preventing the physiological death of cancerous cells. To avert this, we targeted the transcriptional upregulation of p21waf1/cip1 (p21)...
Main Authors: | Thong C. Ma, Brett Langley, Brian Ko, Na Wei, Irina G. Gazaryan, Neela Zareen, Darrell J. Yamashiro, Dianna E. Willis, Rajiv R. Ratan |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2013-01-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996112003038 |
Similar Items
-
Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
by: Matthew E Cockman, et al.
Published: (2019-09-01) -
Neuroprotective Effect of HIF Prolyl Hydroxylase Inhibition in an In Vitro Hypoxia Model
by: Maria Savyuk, et al.
Published: (2020-07-01) -
Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases
by: Orjon Rroji, et al.
Published: (2021-01-01) -
Prolyl hydroxylases:cloning and characterization of novel human and plant prolyl 4-hydroxylases, and three human prolyl 3-hydroxylases
by: Fonsén, P. (Päivi)
Published: (2007) -
Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
by: Ruth X. Wang, et al.
Published: (2021-01-01)